Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llae433 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Sara Cacciapuoti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Psoriasis, Quality of Life, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
Psoriasis may significantly affect the health-related quality of life (HRQoL) of patients. Clinical assessment has been combined with HRQoL scores to evaluate the ways in which cutaneous disease affects patients. Tildrakizumab is a humanized IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23 and is approved for the management of moderate-to-severe plaque psoriasis.
Objectives
To evaluate the impact of tildrakizumab treatment on the psychological symptoms experienced by patients with moderate-to-severe plaque psoriasis.
Methods
A 36-week observational study that enrolled patients with psoriasis who initiated treatment with tildrakizumab 100 mg was carried out. The Dermatology Life Quality Index (DLQI) and Skindex-16 questionnaires were administered at baseline and at weeks 12, 24 and 36. Psoriasis Area Severity Index (PASI), body surface area (BSA) involvement (%) and a visual analogue scale for pruritus (p-VAS) were also assessed at baseline and at each follow-up visit.
Results
Thirty-four patients were enrolled. Baseline mean (SD) PASI score and BSA involvement were 28.4 (5.6) and 38.8 (21.4), respectively. The mean (SD) DLQI, Skindex-16 and p-VAS scores at baseline were 26.4 (3.2), 68 (5.8) and 8.2 (SD not available for p-VAS). Clinical improvement was assessed at weeks 12 [PASI: 12.4 (4.2); BSA involvement: 16.5 (7.3)], 24 [PASI: 4.2 (2.8); BSA involvement: 6.1 (3.1)] and 36 [PASI: 3.6 (3.2); BSA involvement: 4.2 (1.37)]. Clinical improvement was accompanied by an improvement in quality of life at weeks 16 [DLQI: 15.5 (2.9); Skindex-16: 28.2 (4.2); p-VAS: 3.8], 24 [DLQI: 8.2 (1.4); Skindex-16: 16.2 (3.6); p-VAS: 2.6] and 36 [DLQI: 3.1 (2.4); Skindex-16: 9.3 (2.8); p-VAS: 2.8]. Our study also confirmed the safety of tildrakizumab in real-life settings, with no treatment discontinuation due to inefficacy or adverse events.
Conclusions
Our results confirm tildrakizumab as an effective treatment option for improving the HRQoL of patients with psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Teresa Battista, Luca Potestio, Angelo Ruggiero
Zitieren
APA
Cacciapuoti, S., Battista, T., Potestio, L., Scalvenzi, M., Megna, M., & Ruggiero, A. (2025). Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae433
Vancouver
Cacciapuoti S, Battista T, Potestio L, Scalvenzi M, Megna M, Ruggiero A. Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llae433
BibTeX
@article{Cacciapuoti2025,
author = {Cacciapuoti, Sara and Battista, Teresa and Potestio, Luca and Scalvenzi, Massimiliano and Megna, Matteo and Ruggiero, Angelo},
title = {Impact of tildrakizumab on the quality of life of patients with moderate-to-severe psoriasis: a 36-week prospective monocentric real-life observational study},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llae433}
}
EUVIMED